Wu Hsi-Chin, Lin Cheng-Chieh, Chen Wen-Chi, Chen Huey-Yi, Tsai Fuu-Jen
Department of Urology, China Medical College Hospital, Taichung, Taiwan.
Eur Urol. 2003 Feb;43(2):197-200. doi: 10.1016/s0302-2838(02)00541-9.
Osteocalcin is a vitamin-K dependent protein which is related to the metabolism of bone and calcium. The formation or progression of prostate cancer is presumed to be associated with the osteocalcin gene. The most frequently seen polymorphism is HindIII which is located at the promoter region. HindIII is therefore a possible genetic marker in the search for the association between prostate cancer and normal control subjects.
In our study, a normal control group of 132 healthy people and 96 patients with prostate cancer were examined. The polymorphism was seen following polymerase chain reaction (PCR) based restriction analysis.
The result revealed significant differences between normal individuals and cancer patients (p=0.034) and the distribution of the "CC" homozygote in the control group was higher than that in the patient group. No statistical differences were found in clinical staging and grading. The 54 patients who received hormone therapy were further categorized into response and non-response groups, statistical differences between these two groups were revealed (p=0.007, Fisher's exact test).
Based on our results, we conclude that the HindIII polymorphism of the osteocalcin gene is a suitable genetic marker of prostate cancer which can be used in the prediction of the outcome of patients who receive hormone therapy.
骨钙素是一种维生素K依赖蛋白，与骨和钙的代谢相关。前列腺癌的形成或进展被认为与骨钙素基因有关。最常见的多态性是位于启动子区域的HindIII。因此，HindIII可能是寻找前列腺癌与正常对照者之间关联的一种遗传标记。
在我们的研究中，对132名健康人的正常对照组和96名前列腺癌患者进行了检查。通过基于聚合酶链反应（PCR）的限制性分析观察到多态性。
结果显示正常个体与癌症患者之间存在显著差异（p = 0.034），对照组中“CC”纯合子的分布高于患者组。在临床分期和分级方面未发现统计学差异。将接受激素治疗的54例患者进一步分为反应组和无反应组，两组之间存在统计学差异（p = 0.007，Fisher精确检验）。
基于我们的结果，我们得出结论，骨钙素基因的HindIII多态性是前列腺癌的一个合适的遗传标记，可用于预测接受激素治疗患者的预后。
